The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers
Authors:
- P. RolanPRP. Rolan
- 1 February 1996
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 41 (2) , 141-147
Abstract
1 311C90 is a novel and selective agonist at 5‐HT1D receptors, with central and peripheral actions, currently in development for the acute oral treatment of migraine.2 The pharmacokinetic and tolerability profiles of single oral doses from 1–50 mg 311C90 were investigated in 12 healthy male volunteers in a double‐blind, placebo‐controlled, dose‐escalating study.3 311C90 was well tolerated with most adverse experiences of mild and transient nature.4 Absorption was rapid with dose‐independent kinetics. Median tmax was 2–4 h although 50–85% of eventual Cmax was attained within 1 h. The t1/2 was 2.5‐3 h with a high apparent plasma clearance (CL/F > 2000 ml min‐1) and apparent volume of distribution (VZ/F) of 400–5001.5 Three metabolites were detected in plasma and urine, one of which, the N‐desmethyl metabolite, has 5‐HT1D agonist activity.6 311C90 showed no clinically significant effects on blood pressure, heart rate, ECG or laboratory variables at any dose and demonstrated a tolerability and pharmacokinetic profile compatible with an acute oral migraine treatment.Keywords
This publication has 7 references indexed in Scilit:
- Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)‐I D Receptor Agonist 311C90Headache: The Journal of Head and Face Pain, 1994
- SumatriptanDrugs, 1994
- Inhibition by sumatriptan of central trigeminal neurones only after blood‐brain barrier disruptionBritish Journal of Pharmacology, 1993
- SumatriptanDrugs, 1992
- Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraineTrends in Pharmacological Sciences, 1992
- Mode of action of the anti-migraine drug sumatriptanTrends in Pharmacological Sciences, 1991
- The Clinical Pharmacology, Pharmacokinetics and Metabolism of SumatriptanEuropean Neurology, 1991